# Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites

> **NCT04051112** · PHASE1 · COMPLETED · sponsor: **Sichuan Clover Biopharmaceuticals, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Malignant Ascites

## Interventions

- **DRUG:** SCB-313

## Key facts

- **NCT ID:** NCT04051112
- **Lead sponsor:** Sichuan Clover Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-28
- **Primary completion:** 2021-12-24
- **Final completion:** 2022-04-21
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2022-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04051112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04051112, "Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04051112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*